panCELLa seeks to provide absolute control of deregulated cell proliferation. panCELLa's innovative technology is based on creating a tight link between a drug inducible suicide gene and a gene essential to cell division. This mechanism enables dividing, potentially malignant cells to be eliminated at will before or after transplantation into patients.
Through panCELLa, Dr. Keating and Dr. Nagy are seeking to create an effective cell therapy derived from stem cells, which are modified to provide a very high level of safety before and after the cells are introduced to the patient.
panCELLa partners with companies developing cell therapies from embryonic (ES)and induced pluripotent (iPS). With these therapeutic applications come critical and important challenges – uncontrolled proliferation and genetic mutations -- that pose safety risks to patients. panCELLa offers a technological solution to these challenges.
panCELLa, with its proprietary FailSafe Cells, has the capability to define, quantify and decrease the risk of cell therapy to an absolutely negligible level, accelerating cell therapies to patients. It is panCELLa’s objective to create universal, cost-effective, “off the shelf” fail-safe therapeutic cell products and to assist the pharmaceutical and biotechnology sectors in creating their own FailSafe cell lines.
“Man is the only creature that dares to light a fire and live with it.
he alone has learned to put it out.”
~Henry Jackson Vandyke, Jr.